Leading International Investment Research

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Leading International Investment Research, Edison Investment Research

Equity Bottom-Up

Newron Pharmaceuticals / Equity Bottom-Up

<p>On 4 May Newron Pharmaceuticals announced that the pivotal Rett syndrome STARS study of sarizotan had not met the primary or any secondary endpoints. The company will focus now on its novel schizophrenia drug, Evenamide. This clinical programme, due to resume in 2020, is on hold due to COVID-19. Newron drew a €7.5m EIB loan on 15 April and had €39m in cash in December 2019.</p>

On 4 May Newron Pharmaceuticals announced that the pivotal Rett syndrome STARS study of sarizotan had not met the primary or any secondary endpoints. The company will focus now on its novel schizophrenia drug, Evenamide. This clinical programme, due to resume in 2020, is on hold due to COVID-19. Newron drew a €7.5m EIB loan on 15 April and had €39m in cash in December 2019.

Newron Pharmaceuticals - Sarizotan fails to shine